{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:24:47Z","timestamp":1782491087739,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1245\/s10434-020-08918-4","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T19:09:24Z","timestamp":1596481764000},"page":"1118-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6898","authenticated-orcid":false,"given":"Aditi","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snita","family":"Sinukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loma","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutan","family":"Jumle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakina","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"8918_CR1","doi-asserted-by":"crossref","unstructured":"Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1\u20135.","DOI":"10.1016\/j.ijgo.2013.10.001"},{"key":"8918_CR2","doi-asserted-by":"publisher","unstructured":"Bhatt A, Glehen O. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7:188\u201397. https:\/\/doi.org\/10.1007\/s13193-016-0501-9.","DOI":"10.1007\/s13193-016-0501-9"},{"key":"8918_CR3","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","volume":"19","author":"D Baratti","year":"2012","unstructured":"Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416\u201324.","journal-title":"Ann Surg Oncol."},{"key":"8918_CR4","doi-asserted-by":"publisher","unstructured":"Deraco M1,\u00a0Sinukumar S2,\u00a0Salcedo-Hern\u00e1ndez RA3,\u00a0Rajendra VJ4,\u00a0Baratti D5,\u00a0Guaglio M6,\u00a0Nizri E7,\u00a0Kusamura S8. Clinicopathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy: largest single-institute experience. Eur J Surg Oncol.\u00a02019;45:2103\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.021. Epub 13 June 2019.","DOI":"10.1016\/j.ejso.2019.06.021"},{"key":"8918_CR5","doi-asserted-by":"crossref","unstructured":"Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol. 2010;75:27e42.","DOI":"10.1016\/j.critrevonc.2009.10.003"},{"key":"8918_CR6","doi-asserted-by":"crossref","unstructured":"Huang LW, Garrett AP, Schorge JO, Michael G, BellAD, Welch RW, et al. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol. 2000;114:93e9.","DOI":"10.1309\/P51M-B66M-JFKW-ER5A"},{"key":"8918_CR7","doi-asserted-by":"publisher","unstructured":"Albanese AM1,\u00a0Albanese EF,\u00a0Mi\u00f1o JH,\u00a0G\u00f3mez E,\u00a0G\u00f3mez M,\u00a0Zandomeni M,\u00a0Merlo AB. Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas. Surg Radiol Anat.\u00a02009;31:369\u201377. https:\/\/doi.org\/10.1007\/s00276-008-0456-9. Epub 14 January 2009.","DOI":"10.1007\/s00276-008-0456-9"},{"key":"8918_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-540-30760-0_2","volume-title":"Advances in Peritoneal Surface Oncology","author":"Y Yonemura","year":"2007","unstructured":"Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. In: Gonzalez-Moreno S (ed) Advances in Peritoneal Surface Oncology. Springer-Verlag, Berlin Heidelberg, Germany, 2007, pp 11\u201323."},{"key":"8918_CR9","doi-asserted-by":"publisher","unstructured":"Chi DS1,\u00a0Bristow RE,\u00a0Armstrong DK,\u00a0Karlan BY. Is the easier way ever the better way? J Clin Oncol.\u00a02011;29:4073\u20135. https:\/\/doi.org\/10.1200\/jco.2011.35.9935. Epub 19 September 2011.","DOI":"10.1200\/jco.2011.35.9935"},{"key":"8918_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3978\/j.issn.2072-1439.2010.02.03","volume":"2","author":"K Papademetriou","year":"2010","unstructured":"Papademetriou K, Ardavanis A, Kountourakis P. Neoadjuvant therapy for locally advanced breast cancer: focus on chemotherapy and biological targeted treatments\u2019 armamentarium. J Thoracic Dis. 2010;2:160\u201370. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2010.02.03.","journal-title":"J Thoracic Dis."},{"issue":"128","key":"8918_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ygyno.2012.11.007","volume":"2013","author":"J Hynninen","year":"2013","unstructured":"Hynninen J, Lavonius M, Oksa S, et al. Is perioperative visual estimation of intraabdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol. 2013;128:229\u201332, 2013.","journal-title":"Gynecol Oncol."},{"key":"8918_CR12","doi-asserted-by":"publisher","unstructured":"Goswami G1,\u00a0Kammar P2,\u00a0Mangal R1,\u00a0Shaikh S3,\u00a0Patel MD3,\u00a0Bhatt A3. Accuracy of CT scan in predicting the surgical PCI in patients undergoing cytoreductive surgery with\/without HIPEC: a prospective single-institution study. Indian J Surg Oncol.\u00a02019;10:296\u2013302. https:\/\/doi.org\/10.1007\/s13193-019-00914-9. Epub 28 Mar 2019.","DOI":"10.1007\/s13193-019-00914-9"},{"key":"8918_CR13","doi-asserted-by":"publisher","unstructured":"Lim MC1,\u00a0Song YJ,\u00a0Seo SS,\u00a0Yoo CW,\u00a0Kang S,\u00a0Park SY. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer. Onkologie.\u00a02010;33:324\u201330. https:\/\/doi.org\/10.1159\/000313823. Epub 2010 May 14.","DOI":"10.1159\/000313823"},{"key":"8918_CR14","doi-asserted-by":"publisher","unstructured":"Sinukumar S,\u00a0Rajan F,\u00a0Mehta S,\u00a0Damodaran D,\u00a0Zaveri S,\u00a0Kammar P, et al. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube, and primary peritoneal cancer: a study by INDEPSO. Eur J Surg Oncol.\u00a02019. pii: S0748-7983(19)30304\u2013X. https:\/\/doi.org\/10.1016\/j.ejso.2019.02.031.","DOI":"10.1016\/j.ejso.2019.02.031"},{"key":"8918_CR15","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.","DOI":"10.1056\/NEJMoa1708618"},{"key":"8918_CR16","unstructured":"NCCN Guidelines for ovarian cancer. Retrieved 4 March 2020 at https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/ovarian-patient.pdf."},{"key":"8918_CR17","unstructured":"United States Department of Public Health and Human Services, NIH, NCI: Common Toxicity Criteria for Adverse Events (CTCAE). National Cancer Institute, June 2010. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE_Vers._4.03_2010-06-14;_QuickReference_5x7.pdf."},{"key":"8918_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"key":"8918_CR19","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ejso.2019.07.019","volume":"45","author":"A Bhatt","year":"2019","unstructured":"Bhatt A, Yonemura Y, Benzerdjeb N, et al. Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential: a prospective multi-centric study. Eur J Surg Oncol. 2019;45:2398\u2013404.","journal-title":"Eur J Surg Oncol."},{"key":"8918_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","volume":"28","author":"WG McCluggage","year":"2015","unstructured":"McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, et al. International collaboration on cancer reporting: data set for reporting of ovary, fallopian tube, and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2015;28:1101\u201322. https:\/\/doi.org\/10.1038\/modpathol.2015.77.","journal-title":"Mod Pathol."},{"key":"8918_CR21","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1245\/s10434-020-08234-x","volume":"27","author":"A Bhatt","year":"2020","unstructured":"Bhatt A,\u00a0Yonemura Y,\u00a0Mehta S,\u00a0Benzerdjeb N,\u00a0Kammar P,\u00a0Parikh L,\u00a0et al. The Pathologic Peritoneal Cancer Index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann Surg Oncol.\u00a02020;27:2985\u201396. https:\/\/doi.org\/10.1245\/s10434-020-08234-x.\u00a0","journal-title":"Ann Surg Oncol."},{"key":"8918_CR22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33:2457\u201363. https:\/\/doi.org\/10.1200\/JCO.2014.60.5212.","journal-title":"J Clin Oncol."},{"key":"8918_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","volume":"24","author":"A Di Giorgio","year":"2017","unstructured":"Di Giorgio\u00a0A,\u00a0De Iaco\u00a0P,\u00a0De Simone\u00a0M, et\u00a0al.\u00a0Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases. Ann Surg Oncol.\u00a02017;24:914\u201322.","journal-title":"Ann Surg Oncol."},{"key":"8918_CR24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of566 patients.\u00a0Eur J Surg Oncol.\u00a02013;39:1435\u201343. https:\/\/doi.org\/10.1016\/j.ejso.2013.09.030.","journal-title":"Eur J Surg Oncol."},{"key":"8918_CR25","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380:822\u201332.","journal-title":"N Engl J Med."},{"key":"8918_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/02656736.2017.1367846","volume":"34","author":"M Alyami","year":"2018","unstructured":"Alyami\u00a0M,\u00a0Kim\u00a0BJ,\u00a0Villeneuve\u00a0L, et\u00a0al.\u00a0Ninety-day postoperative morbidity and mortality using the National Cancer Institute\u2019s common terminology criteria for adverse events better describe postoperative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia.\u00a02018;34:532\u20137.","journal-title":"Int J Hyperthermia."},{"issue":"Suppl 1","key":"8918_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13193-019-00877-x","volume":"10","author":"S Sinukumar","year":"2019","unstructured":"Sinukumar S, Mehta S, Damodaran D, et al. Failure-to-rescue following cytoreductive surgery with or without HIPEC is determined by the type of complication: a retrospective study by INDEPSO.\u00a0Indian J Surg Oncol. 2019;10(Suppl 1):71\u20139. https:\/\/doi.org\/10.1007\/s13193-019-00877-x.","journal-title":"Indian J Surg Oncol."},{"key":"8918_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ejso.2019.01.009","volume":"45","author":"A Bhatt","year":"2019","unstructured":"Bhatt A, Sinukumar S, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer: a study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO). Eur J Surg Oncol. 2019;45:666\u201371. https:\/\/doi.org\/10.1016\/j.ejso.2019.01.009. Epub 9 January 2019.","journal-title":"Eur J Surg Oncol."},{"key":"8918_CR29","doi-asserted-by":"publisher","unstructured":"Sugarbaker PH1. Avoiding diverting ileostomy in patients requiring complete pelvic peritonectomy. Ann Surg Oncol.\u00a02016;23:1481\u20135. https:\/\/doi.org\/10.1245\/s10434-015-4961-x. Epub 5 November 2015.","DOI":"10.1245\/s10434-015-4961-x"},{"issue":"Suppl 1","key":"8918_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13193-019-00875-z","volume":"10","author":"A Bhatt","year":"2019","unstructured":"Bhatt A, Sinukumar S, Rajan F, Damodaran D, Ray M, Zaveri S, et al. Impact of radicality versus timing of surgery in patients with advanced ovarian cancer (stage III C) undergoing CRS and HIPEC: a retrospective study by INDEPSO. Indian J Surg Oncol. 2019;10(Suppl 1):57. https:\/\/doi.org\/10.1007\/s13193-019-00875-z.","journal-title":"Indian J Surg Oncol."},{"key":"8918_CR31","doi-asserted-by":"publisher","unstructured":"Harlaar NJ1,\u00a0Koller M1,\u00a0de Jongh SJ2,\u00a0van Leeuwen BL1,\u00a0Hemmer PH1,\u00a0Kruijff S1,\u00a0et al.. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol Hepatol.\u00a02016;1:283\u201390. https:\/\/doi.org\/10.1016\/s2468-1253(16)30082-6. Epub 2016 Sep 17.","DOI":"10.1016\/s2468-1253(16)30082-6"},{"key":"8918_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13193-016-0518-0","volume":"7","author":"PH Sugarbaker","year":"2016","unstructured":"Sugarbaker PH. Preoperative assessment of cancer patients with peritoneal metastases for complete cytoreduction. Indian J Surg Oncol. 2016;7:295\u2013302.","journal-title":"Indian J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08918-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:05:50Z","timestamp":1627945550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08918-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["8918"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08918-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"20 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}